Otonomy Announces Multiple Presentations at Association for Research in Otolaryngology Annual Meeting
- Presentation of positive top-line clinical results for OTO-313 in tinnitus and OTO-413 in hearing loss
- Supportive preclinical data to be presented for OTO-825 gene therapy and OTO-510 otoprotection program
“We are pleased to have the opportunity to present clinical results for OTO-313 and OTO-413 during ARO, which is the premier meeting of research scientists in the neurotology field,” said
- “From research to preclinical development: translating in vitro/ex vivo research into clinically relevant in vivo studies for hearing loss” by
Bonnie Jacques, Ph.D.
Presentations related to Otonomy’s clinical programs for tinnitus and hearing loss:
- "A Phase 1/2 study of OTO-313 given as a single intratympanic injection in patients with moderate to severe, persistent tinnitus” by Maxwell et al., on
- "A first-in-human study of OTO-413, an intratympanic sustained-exposure formulation of BDNF, for the treatment of speech-in-noise hearing impairment” by Anderson et al., on
Additional presentations related to
- "Characterization of novel AAV capsid variants for delivery of GJB2 gene therapy for congenital hearing loss" a joint presentation from
Otonomyand Applied Genetics Technology Corporation(AGTC) by Uribe et al., on February 24.
- “Identification and characterization of a novel therapeutic class for protection against cisplatin-induced hearing loss” by Tsivkovskaia et al., on
- “Characterization of a TrkB mAb agonist for the treatment of speech-in-noise hearing difficulties (cochlear synaptopathy)” by Tsivkovskaia et al., on
- “Novel tools to probe neurotrophic signaling in cochlear neurons: fab fragments derived from Trk-selective agonist monoclonal antibodies are potent and selective antagonists of the TrkB and TrkC receptors” by Siegel et al., on
Source: Otonomy, Inc.